StreetAlpha.app
Home › Stocks › ACRS

Aclaris Therapeutics, Inc. (ACRS)

Healthcare
$3.44
▼ −1.71%
LAST CLOSE · NOV 20

Aclaris Therapeutics develops prescription drug candidates, testing them in clinical trials and planning to sell approved products through partners. It last closed at $3.44 on Nov 20, down 1.71% on the day. The next earnings report for ACRS is expected around Thu, Feb 25, 2027. For the quarter ended Sep 2026, ACRS reported EPS of -$0.12 on revenue of $1.5M, with revenue down 55.1% from a year ago. Over its last 8 reports the stock moved an average of 3.1% the session after earnings. Over the last 12 months ACRS insiders bought $0 of stock on the open market and sold $1.4M, according to SEC Form 4 filings.

AI Auto Pilots
Is ACRS in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ACRS.

Key Stats

Last 12 months
Results
Revenue
$6.4M
−59.3% vs a year ago
Net income
−$79.6M
−1244.1% margin
EPS (diluted)
−$0.59
Free cash flow
−$75.3M
−1176.6% margin
Valuation
Market cap
$545.6M
158.6M shares
P/E
–
No P/E while losing money
Price to sales
85.2
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$20.4M
At Sep 30
Shareholder equity
$166.8M
Shares outstanding
158.6M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $6.8M$6.8MFY2021FY2022: $29.8M$29.8MFY2022FY2023: $31.2M$31.2MFY2023FY2024: $18.7M$18.7MFY2024FY2025: $7.8M$7.8MFY2025

From ACRS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Feb 25
Estimated date · Time not announced
Reported EPS
-$0.12
Quarter ended Sep 2026
Year ago EPS
-$0.12
Same quarter last year
Revenue
$1.5M
−55.1% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$1.21Dec '24Mar 2025: -$0.12Mar '25Jun 2025: -$0.13Jun '25Sep 2025: -$0.12Sep '25Dec 2025: -$0.16Dec '25Mar 2026: -$0.15Mar '26Jun 2026: -$0.15Jun '26Sep 2026: -$0.12Sep '26Latest -$0.12
Revenue by quarter
Dec 2024: $9.2MDec '24Mar 2025: $1.5MMar '25Jun 2025: $1.8MJun '25Sep 2025: $3.3MSep '25Dec 2025: $1.3MDec '25Mar 2026: $2.0MMar '26Jun 2026: $1.6MJun '26Sep 2026: $1.5MSep '26Latest $1.5M
How ACRS moved after its last 8 reports
Average move the session after a report ±3.1%
Oct 27, 2026Time not announced0.0%
Aug 6, 2026Time not announced−4.3%
May 7, 2026Time not announced+1.7%
Feb 26, 2026Time not announced−5.4%
Nov 6, 2025Time not announced+0.4%
Aug 7, 2025Time not announced+1.3%
May 8, 2025Time not announced+4.8%
Feb 27, 2025Time not announced−7.1%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on ACRSStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
Analyst calls from around the web
Last 90 days on ACRS: 0 upgrades, 1 downgrade, 0 initiations
WedbushDowngrade
Nov 20Neutral 

StreetAlpha's curated list of analyst calls collected from around the web. It may be incomplete or inaccurate, is not a consensus and is not advice.

AI Starter and AI Pro
Full analyst coverage on ACRS
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on ACRS

Technical Analysis

ACRS · as of the Nov 20 close · updated each morning
Downtrend

The stock is 11% below its 20 day and 22% below its 50 day average. It is 32% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 39). The nearest support is the Pivot S1 at $3.38, and the nearest resistance the Pivot at $3.46.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityHigh, 8.7%/day
Key levels
$6.6052 week high+91.9%
$5.00100 day average+45.3%
$4.54200 day average+32.0%
$4.2150 day average+22.4%
$4.08Swing high (Nov 2)+18.6%
$3.8220 day average+11.0%
$3.52Pivot R1+2.3%
$3.46Pivot+0.6%
$3.44Last close
$3.38Pivot S1−1.7%
$3.25Swing low (Oct 16)−5.5%
$2.3452 week low−32.0%
Indicators
RSI (14)38.98Weak, oversold below 30Neutral
MACD-0.17Below its signal lineBearish
Stochastic19.6Near the bottom of its rangeOversold
ADX (14)30.3Trending down
Williams %R-83.8Oversold below −80, overbought above −20Oversold
CCI (20)-110.8Oversold below −100, overbought above 100Oversold
Rate of change−11.8%Change over 10 sessionsBearish
ATR (14)$0.30Typical daily range, 8.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ACRS

What happened before

See how ACRS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow ACRS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How ACRS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2015.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for ACRSHow many large options trades hit ACRS, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

ACRS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲96 buying vs 61 selling
  • ▲Held by funds +11.0 pts
  • ▲Funds holding +18
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding167149+12.1%
In funds' top 1065+20.0%
Held by funds87.3%76.4%+11.0 pts
New / increased38 / 5827 / 690.0%
Reduced / sold out40 / 2131 / 14+35.6%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ACRS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

ACRS Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$1.4M1 sale · 1 insider
2026-04 sold $1.4MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Apr 23Braden Michael Leonard10% ownerSale300,000$4.53$1.4M
Nov 19, 2024Anand MehraDirectorBuy666,666$2.25$1.5M
Every insider buy and sale for ACRS over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See ACRS insider trades →

From SEC Form 4 filings by ACRS's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ACRS is in one of them and how their past ACRS trades turned out.

ACRS in the AI portfolios
Loading…

ACRS News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ACRS in an article yet. Here's the latest on the wider market.

ACRS in the news

About Aclaris Therapeutics

Aclaris Therapeutics is a pharmaceutical company based in Wayne, Pennsylvania. It develops prescription drug product candidates and tests them in clinical trials, relying on outside research organizations to run much of that work. The company plans to bring approved products to patients through outside partners, who would sell them to patients, insurers and government health programs. It also depends on outside suppliers to manufacture the drug supplies used in its trials.

Headquarters
Wayne, PA